Drug Discovery World

MARCH 13, 2024

Dr Aarti Gokhale, Senior Director Business Development — APAC at Yourgene Health, explains why it has become such an important market: “Singapore was one of the first Asian countries to invest in building out an ecosystem for scientific research. UK-based molecular diagnostics group Yourgene operates in Singapore.

Life Science 67

Life Science Genome Genomics Research 67

Pharmaceutical Technology

JULY 29, 2022

According to Bumcrot, regRNAs are “RNAs that arise out of the non-coding genome”. In order to achieve these plans, CAMP 4’s CEO, Josh Mandel-Brehm stated the company will prioritise raising capital through partnerships and business development. Future Possibilities.

RNA 245

RNA Gene Expression Gene Gene Therapy 245

pharmaphorum

SEPTEMBER 28, 2022

” ArsenalBio’s platform makes use of automation, large-scale genome engineering, using technologies like CRISPR-based gene-editing, and machine learning and artificial intelligence algorithms to design, build, and test cell therapies.

Gene Editing 59

Gene Editing Genome Genomics Engineer 59

The Pharma Data

JUNE 7, 2023

. “Complementing in-house expertise with external collaboration continues to be a priority in areas of high unmet medical need where insufficient, or no treatment options are currently available,” said Friedemann Janus, acting Head of Business Development and Licensing/Open Innovation, Pharmaceuticals Division, Bayer.

Gene Therapy 40

Gene Therapy Gene Gene Editing In-Vivo 40

Pharmaceutical Technology

DECEMBER 22, 2022

The funding will offer capital to extend Blueprint’s varied pipeline toward marketing as well as to continue seeking strategic and synergistic business development prospects. Deerfield and Illumina win the Research and Development award this year due to their commitment to research into AI-driven therapies. Innovation.

Insulin 130

Insulin Production Development Genetics 130

The Pharma Data

JANUARY 12, 2021

Marianne De Backer, Head of Business Development & Licensing in Bayer’s Pharmaceuticals Division, pictured above. As a result, the company settled on four areas of focus – iPSC, allogenic CAR-T, genome mutations and gene editing. Photo courtesy of Bayer.

Gene Therapy 52

Gene Therapy Gene Gene Editing Licensing 52

The Pharma Data

NOVEMBER 3, 2020

LogicBio’s proprietary genome editing technology platform, GeneRide, enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. LogicBio is headquartered in Lexington, Mass. For more information, please visit www.logicbio.com.

Clinical Trials 52

Clinical Trials Clinical Trials Gene Editing Genome 52

The Pharma Data

NOVEMBER 5, 2020

VectivBio AG – Based in Switzerland, VectivBio named Sarah Holland as chief business officer and Aditya Venugopal as head of business development. Deep Genomics – Toronto-based Deep Genomics appointed Amanda Kay to the newly-created role of chief business officer.

Genome 40

Genome Genomics Medicine Life Science 40

Drug Discovery World

APRIL 17, 2024

We can envision it this way: at a given genomic site, some TFs are engaged in activating the gene, while others are engaged in suppressing it. He previously held key business development and operations leadership roles at leading biotech companies, including at Biogen and Genzyme.

Gene Expression 57

Gene Expression Gene Genetic Disease RNA 57

pharmaphorum

MARCH 8, 2022

After a few years, I decided I wanted to move into the commercial side of the business, so I completed an MBA and went on to hold various positions in Corporate Business Development, Life Science and Healthcare. I have been general manager for Merck Healthcare UK & Ireland since 2020.

Life Science 98

Life Science Engineer Scientist Doctors 98

Drug Discovery World

APRIL 29, 2024

Hall has been with the company for more than 16 years, including as Chief Commercial Officer, and was previously Head of Business Development in Europe for Cyprotex. Bironneau brings over two decades of commercial leadership experience, including as Vice President, Global Sales & Business Development at Axplora and Novasep.

Drugs 52

Drugs Sales Gene Therapy Life Science 52

The Pharma Data

JANUARY 4, 2021

Longwood has a robust research department with 7 post doctorates conducting research in molecular biology, microbiology, genomics, cancer biology, and immunology and publishing over 75 publications in different scientific journals in the past 5 years. Barber also serves on Kiromic’s Scientific Advisory Board. About Longwood University.

In-Vivo 40

In-Vivo Development Big Data Immune Response 40

The Pharma Data

OCTOBER 14, 2020

They offer access to an intact genome which allows whole genome sequencing without a background. We are looking forward to exploring business development opportunities with innovative companies in these two fields of use who are interested in a technology platform offering a real competitive advantage” said Savran.

Clinical Trials 40

Clinical Trials Clinical Trials Trials Genome 40

Drug Discovery World

SEPTEMBER 6, 2022

Fully booked service providers for manufacturing and sample analyses and more immune-oriented use of gene and cell therapies.” – CBO Aino Kalervo, and VP of Business Development? Research into genomic medicines is only at its infancy. .” – Andrew Scharenberg, Umoja Biopharma CEO. .

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

The Pharma Data

OCTOBER 26, 2020

50%) with no EGFR or ALK genomic tumor aberrations. L1 expression with no EGFR or ALK genomic tumor aberrations at the IASLC 2020 North America Conference on Lung Cancer (NACLC). The FDA has granted V181, the company’s investigational dengue vaccine in Phase 1 development, Fast Track designation.

Sales 40

Sales Vaccination Vaccine Production 40

Drug Discovery World

NOVEMBER 8, 2023

Kathrin Herbst, PhD, Director of Science & Business Development, Lightcast, on: ‘A new era of single-cell functional profiling for drug discovery’. CTO, Sphere Fluidics Limited, on: “Picodroplets for cell line engineering: a novel automation approach”.

Antibody 62

Antibody Engineer Protein Scientist 62

The Pharma Data

NOVEMBER 15, 2020

Prior to Celgene, she held leadership roles in marketing, sales and new business development from 2002 to 2011 at Johnson & Johnson. Most recently, she was a senior executive at Celgene Corporation, where she led corporate strategy from 2012 to 2017. Before that, Ms.

Clinical Trials 40

Clinical Trials Clinical Trials Production Trials 40

The Pharma Data

AUGUST 6, 2020

FDA for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. This approval was based on the Phase 3 CheckMate -9LA study. In May, the company announced the U.S.

Production 52

Production Branding Marketing Licensing 52

Pharmaceutical Technology

MARCH 20, 2023

One significant growth area is the rise of genomics. Genomics is set to have a major impact on understanding, preventing, and treating a huge range of diseases; cell and gene therapies will bolster oncology investment, for example, with several such drugs currently in development.

Gene Therapy 225

Gene Therapy Genome Genomics Gene 225